Portfolio Highlights: Clinical and Financing Updates of QurAlis, Apeiron and QureBio
Time: 2022-04-29
Source: Viva Biotech
[Abstract]:Over the past 2 month, our portfolio companies have had great progress.

Dr. Kasper Roet, CEO of QurAlis, selected for the 2022 Henri Termeer Award

BOSTON, April 21, 2022 -- The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, announced the recipients of the 2022 Henri Termeer Transatlantic Connections Award. Dr. Kasper Roet, co-founder and CEO of QurAlis, a biotech company that invested and incubated by Viva BioInnovator, was recognized as an honoree at the Innovation for Health conference.


Apeiron Completed A $17.5 Million Series A Financing and Established A New Strategic Partnership with Viva Biotech

GT Apeiron Therapeutics (“Apeiron”) announced it has completed a $17.5 million Series A financing. Panacea Venture led the investment round with participation from Viva BioInnovator and existing investors. This is the company’s second round of financing in the last year following a Pre-A+ round in May 2021. The investment will enable the company to advance its lead CDK7 program to enter clinical trials, as well as several earlier stage programs.


Leaders from Zhangjiang Biotech and Pharmaceutical Base Visited QureBio for Investigation and Research



On March 4, Lou Qi, General Manager of Zhangjiang Biotech and Pharmaceutical Base, and Cao Li, GM Assistant visited QureBio. Dr. Du Yejie, Vice General Manager of QureBio, accompanied the visit.

Media contact:
Contact Us